On Sept. 20, 2000 Targeted Genetics Corporation (Nasdaq:TGEN - news) an SBIR firm announced that the company has completed its acquisition of Genovo, Inc., a privately held gene therapy company. Genovo's major assets include proprietary AAV-based product development programs in the areas of hyperlipidemia and atherosclerosis; intellectual property covering production, composition of matter and use of AAV-based products and patents related to other viral vector systems; and a product development agreement with Genzyme Corp. in the area of lysosomal storage disorders.
